Search

Your search keyword '"Trejo-Becerril, C."' showing total 40 results

Search Constraints

Start Over You searched for: Author "Trejo-Becerril, C." Remove constraint Author: "Trejo-Becerril, C."
40 results on '"Trejo-Becerril, C."'

Search Results

4. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors

5. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype

8. A phase II trial of epigenetic therapy with hydralazine and magnesium valproate associated to doxorubicin and cyclophosphamide for locally advanced breast cancer

10. Epigenetic therapy and cisplatin chemoradiation in FIGO Stage IIIB cervical cancer.

13. The role of extracellular DNA (exDNA) in cellular processes.

14. Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells.

15. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.

16. Feasibility and antitumor efficacy in vivo , of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer.

17. Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model.

18. Viral inhibitors of NKG2D ligands for tumor surveillance.

19. In vivo rat model to study horizontal tumor progression.

20. Cancer progression mediated by horizontal gene transfer in an in vivo model.

21. DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.

22. Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test.

23. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.

24. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.

25. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.

26. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.

27. Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome.

28. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

29. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.

30. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.

31. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.

32. Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance.

33. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.

34. [Association between presence of anti-Ras and anti-VPH16 E4/E7 antibodies and cervical intraepithelial lesions].

35. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients.

36. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.

37. Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma.

38. Correlation of tumor growth index with early treatment response in cervical carcinoma.

39. Membrane proteins in neoplasic and normal uterine cervix.

40. Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection.

Catalog

Books, media, physical & digital resources